This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
GMED or SONVY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMED vs. SONVY: Which Stock Is the Better Value Option?
HOLX or SONVY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. SONVY: Which Stock Is the Better Value Option?
GMED vs. SONVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
GMED vs. SONVY: Which Stock Is the Better Value Option?
TFX vs. SONVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
TFX vs. SONVY: Which Stock Is the Better Value Option?
HOLX vs. SONVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. SONVY: Which Stock Is the Better Value Option?
HOLX vs. SONVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. SONVY: Which Stock Is the Better Value Option?
HOLX or SONVY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. SONVY: Which Stock Is the Better Value Option?
HOLX vs. SONVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. SONVY: Which Stock Is the Better Value Option?
TMO vs. SONVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. SONVY: Which Stock Is the Better Value Option?
SONVY or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SONVY vs. EW: Which Stock Is the Better Value Option?
SONVY or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SONVY vs. IDXX: Which Stock Is the Better Value Option?
Here's Why Momentum in SONOVA HOLDING (SONVY) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, SONOVA HOLDING (SONVY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
SONOVA HOLDING (SONVY) Is a Great Choice for "Trend" Investors, Here's Why
by Zacks Equity Research
SONOVA HOLDING (SONVY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Momentum in SONOVA HOLDING (SONVY) Should Keep going
by Zacks Equity Research
SONOVA HOLDING (SONVY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein
by Zacks Equity Research
The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein
5 MedTech Stocks to Gain in 2021 as Base Business Recovers
by Urmimala Biswas
These five MedTech stocks, EYE, MRVI, SONVY, SARTF and HSIC, all with a favorable Zacks Rank and growth parameters are expected to put up a robust performance in 2021.
5 Soaring MedTech Stocks to Buy for More Growth in 2021
by Urmimala Biswas
We have selected five MedTech growth stocks with further rooms for improvement in 2021.
Idexx (IDXX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical (ISRG) posted solid numbers in the third quarter, courtesy of rising customer adoption of procedures and growth in system placements.
athenahealth (ATHN) Beats Earnings, Misses Revenues in Q3
by Zacks Equity Research
athenahealth (ATHN) witnessed a year-over-year increase in Q3 revenues on the back of strength in its Business and Services segment.
Here's Why Investors Should Sell Patterson Companies Now
by Zacks Equity Research
Rapidly changing healthcare environment in the United States, unfavorable price movement, a competitive dental products distribution industry and integration risks pose significant challenges for Patterson Companies (PDCO).
Here's Why Investors Should Sell Ecolab (ECL) Right Away
by Zacks Equity Research
Intensifying competition, foreign exchange volatility, higher raw material costs and integration risks are primary headwinds for Ecolab (ECL) as of now.
OPKO Health (OPK) Signs New Agreement with Japan Tobacco
by Zacks Equity Research
OPKO Health's (OPK) new agreement with Japan Tobacco will enhance prospects of its kidney drug RAYALDEE in Japan.
Ecolab (ECL) to Divest Equipment Care Segment, Shares Fall
by Zacks Equity Research
In August, management at Ecolab (ECL) announced that equipment care business has been witnessing a quiet period, registering just 2% growth on a year-over-year basis in the last quarter.
Veeva Systems (VEEV) Rides High on Commercial Cloud Platform
by Zacks Equity Research
The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Veeva's (VEEV) industry-specific focus lends it a significant leverage.